Holen Sie sich die Stockscreener-App
7.4793
2.19%
0.1793
Schlusskurs vom Vortag:
$7.30
Offen:
$7.27
24-Stunden-Volumen:
225.06K
Relative Volume:
0.13
Marktkapitalisierung:
$337.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.57M
KGV:
-3.9024
EPS:
-1.9166
Netto-Cashflow:
$-72.14M
1W Leistung:
+2.05%
1M Leistung:
-85.38%
6M Leistung:
-80.12%
1J Leistung:
-69.55%
1-Tages-Spanne:
$7.1691
$7.5404
1-Wochen-Bereich:
$6.62
$7.56
52-Wochen-Spanne:
$4.01
$54.97
Sionna Therapeutics Inc Stock (SION) Company Profile
Firmenname
Sionna Therapeutics Inc
Sektor
Branche
Telefon
617-819-2020
Adresse
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
7.46 | 330.05M | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
521.01 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.50 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.98 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.18 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.52 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-04 | Eingeleitet | Guggenheim | Buy |
| 2025-03-04 | Eingeleitet | Stifel | Buy |
| 2025-03-04 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Sionna Therapeutics Inc Aktie (SION) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - FinancialContent
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Sionna Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sionna Therapeutics, Inc. (SION) And Encourages Shareholders to Reach Out - ACCESS Newswire
SION INVESTIGATION: Investigation Launched into Sionna - GlobeNewswire
Sionna Therapeutics stock plunges 91% after fai... - Pluang
Securities Fraud Investigation Into Sionna Therapeutics, - GlobeNewswire
Robbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Connect - ACCESS Newswire
Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sionna (SION) Earnings Reading: Profit Per Share Clears Its Benchmark in the Latest Reading; Price Move - vinanet.vn
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - Yahoo Finance
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
2026-08-20 | Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:SION | Press Release - Stockhouse
Sionna (SION) Quarterly Figures: The Bottom-Line Figure Beats Its Comparison in the Current Update; Trading Response: The Share Price Adds 5.22% for the Current SessionTangible Book Value - vinanet.vn
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sionna shares plunge 92% after Phase 2a trial o... - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Sionna Therapeutics (SION) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - WBOC TV
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - FinancialContent
Sionna Therapeutics, Inc. Common Stock (NASDAQ: SION) Stock Price, News & Analysis - Kalkine
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information - Business Wire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Sionna Therapeutics (SION) - GlobeNewswire
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff? - Stocktwits
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
SION INVESTOR ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - The Daily Tribune News
symbol__ Stock Quote Price and Forecast - CNN
Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION) - Business Wire
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - PR Newswire
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep? - Yahoo Finance
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed? - Yahoo Finance
SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - PR Newswire
Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION) - Morningstar
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sionna's SION-719 Failure Changes Everything (Rating Downgrade) - Seeking Alpha
Sionna Therapeutics (NASDAQ:SION) Downgraded to Hold Rating by Lifesci Capital - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by JonesTrading - MarketBeat
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall - Yahoo Finance
SIONNA THERAPEUTICS, INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $5 FROM $53 - webull.com
One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses - finance.yahoo.com
SION Stock Slides, Then Snaps Back As Traders Eye Volatility - StocksToTrade
Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates - GlobeNewswire
Sionna Therapeutics stock falls 92% after SION-719 trial failure - qz.com
BTIG Downgrades Sionna Therapeutics to Neutral From Buy - marketscreener.com
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure - Yahoo Finance
A Quick Look at Today's Ratings for Sionna Therapeutics(SION.US), With a Forecast Between $63 to $63 - Moomoo
SIONNA THERAPEUTICS, INC. : BTIG CUTS TO NEUTRAL FROM BUY - Bitget
Sionna Therapeutics, Inc.Common Stock (SION) Stock Price, News, Quote & History - FinancialContent
Finanzdaten der Sionna Therapeutics Inc-Aktie (SION)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sionna Therapeutics Inc-Aktie (SION) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Jul 07 '26 |
Sale |
44.86 |
85,918 |
3,854,281 |
2,469,959 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
6.11 |
10,250 |
62,628 |
10,250 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Sale |
43.60 |
10,250 |
446,862 |
0 |
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):